All News

December 16 2019

NRG Oncology Trial shows that standard of care chemoradiation for Stage III non-small cell lung cancer is superior to two tested alternatives

Lung cancer is the leading cause of cancer death in the United States and approximately 75-80% of all cases are non-small cell lung cancer (NSCLC). Of these, 30-40% are considered locally advanced and are categorized as either Stage IIIA or IIIB. Read more

December 13 2019

Breast-conserving treatment without surgery not supported at this time: Results of NRG Oncology study BR005

Results from NRG Oncology's BR005 study show that breast-conserving treatment without surgery cannot be recommended, based on the study criteria of clinical complete response, radiological complete response (rCR)/near rCR, and negative tumor bed biopsies. Read more

December 12 2019

Extended letrozole therapy improves disease-free survival (DFS) in postmenopausal women with HR+ breast cancer: 10-year results of NRG Oncology/NSABP B-42 trial

In the updated results from NRG Oncology/NSABP B-42 trial through 10 years of observation, extending letrozole therapy for additional five years after five years of adjuvant endocrine therapy resulted in a statistically significant improvement in the 10-year disease-free survival (DFS) of postmenopausal women with hormone-receptor-positive breast cancer. Read more

November 27 2019

NRG Oncology trial shows immunotherapy is safe following chemoradiotherapy for women with node-positive cervical cancer

Results from the NRG Oncology phase I clinical trial NRG-GOG 9929 show that utilizing the immunotherapy drug ipilimumab after chemoradiotherapy (CRT) is tolerated in the curative treatment of women with lymph node-positive cervical cancer. The maximum tolerated dose of ipilimumab was determined to be 10 mg/kg. Read more

October 10 2019

NRG Oncology Currents October 2019 eNewsletter

NRG Oncology Currents - NRG Oncology's monthly eNewsletter edition for October 2019. Read more

September 29 2019

Trametinib Improves Outcomes for Women with Low-Grade Serous Carcinoma of the Ovary/Peritoneum on NRG Oncology Trial

NRG Oncology and the National Cancer Research Network (NCRN) collaborated on a phase II/III clinical trial NRG-GOG 0281 which compared treatment using the MEK inhibitor trametinib to the physician’s choice of standard of care treatment for women with low-grade serous ovary or peritoneal cancer (LGSOC). Results of this trial indicate that trametinib was able to improve progression-free survival (PFS) and objective response rate (ORR). Improvements in response duration and overall survival (OS) were also observed. These results were presented at the 2019 European Society for Medical Oncology Congress in September 2019. Read more

September 19 2019

Protocol Support Committee – Call for Applications

Do you want to become more involved in NRG Oncology?There is an opportunity to work with your colleagues on the Protocol Support Committee (PSC) Clinical Trial Nurse Committee (CTN), the Clinical Research Associate (CRA) Committee and/or to serve on one of the PSC Working Groups: Education and Training, Mentorship, Protocol Review or Quality Control. Read more

September 19 2019

A Letter from the NRG Oncology Group Chairs on Rare Tumor Trials

We were recently asked to provide a letter to support an NRG Oncology investigator’s response to a query at their institution related to a study not meeting the accrual threshold for remaining open. You likely have some experience with being questioned about maintaining an open study that doesn’t appear to be accruing due to the rare-tumor type involved. We agreed to pull together a letter to provide support, and thought to share this more broadly. Read more

September 16 2019

Reduced-Dose Intensity-Modulated Radiotherapy with Cisplatin Meets Predetermined Benchmarks for Progression-Free Survival and Swallowing-Related Quality of Life for Oropharyngeal Cancer

Results of the NRG Oncology clinical trial NRG-HN002 indicated that the combination of intensity-modulated radiotherapy (IMRT) and cisplatin was able to meet acceptability criteria for progression-free survival (PFS) and swallowing-related quality of life for patients who have p16-positive, non-smoking-associated oropharyngeal cancer. These results were highlighted during the plenary session at the American Society for Radiation Oncology’s (ASTRO) Annual Meeting in September 2019 and this presentation was the recipient of ASTRO and ABR Foundation’s Steven A. Leibel Memorial Award at the Meeting. The abstract was one of four abstracts chosen from over 3,000 submitted abstracts for the plenary session. Read more

September 16 2019

NRG Oncology Substudy Show Cosmetic Changes are Equivalent after Whole Breast Irradiation versus Partial Breast Irradiation for Women with Early Stage Breast Cancer

Results from the Quality of Life substudy of the NRG Oncology clinical trial NSABP B-39/RTOG 0413 indicate that women rated post-lumpectomy partial breast irradiation (PBI) as equivalent to whole breast irradiation (WBI) in terms of cosmetic outcomes and satisfaction from baseline to three years following radiotherapy treatment. Treating physicians from the accruing site rated PBI as inferior to WBI while physicians who performed central review of digital photos blinded to treatment arm and time-point rated cosmetic outcome from PBI equivalent to WBI. These results were presented at the annual meeting of the American Society for Radiation Oncology (ASTRO) during the Plenary Session. The abstract was one of four abstracts chosen from over 3,000 submitted abstracts for the plenary session. Read more

September 16 2019

NRG Oncology Trial Shows no Difference in Pain Response between Stereotactic Body Radiotherapy and Conventional Radiotherapy for Patients with Spinal Metastases

A Phase III, NRG Oncology clinical trial that compared radiosurgery (SRS) or stereotactic body radiotherapy (SBRT) to the conventional radiotherapy (cEBRT) for patients with spinal metastases indicated that there was no statistically significant difference between the treatments for pain response, adverse events, FACT-G, BPI, and EQ-5D scores. These results were presented during the plenary session of the American Society of Radiation Oncology’s (ASTRO) Annual Meeting in September 2019. The abstract was one of four abstracts chosen from over 3,000 submitted abstracts for the plenary session. Read more

September 16 2019

Pre-Salvage RT PSA is Predictive of Hormone Therapy Benefit with Salvage RT for Men with Recurrent Prostate Cancer on NRG Oncology Trial

Initial results of NRG Oncology Clinical Trial RTOG 9601 in men with biochemically recurrent prostate cancer receiving salvage radiotherapy (SRT) demonstrated improvement in OS from the addition of long-term hormone therapy to SRT. However, a secondary analysis indicates that all patients do not benefit and the addition of long-term anti-androgen therapy did not improve overall survival (OS) rates and could increase other-cause mortality (OCM) for some patients depending on pre-treatment PSA level. Read more

September 12 2019

NRG Oncology Highlighted at ASTRO 2019, with all 4 ASTRO Plenary Session Talks Featuring NRG Oncology Research​

Results from twenty-one NRG Oncology clinical trials will be presented at the 2019 American Society for Radiation Oncology (ASTRO) Annual Meeting in Chicago, Illinois this September. All four ASTRO Plenary Session presentations are featuring NRG Oncology research, and these four highly impactful projects were chosen from over 3,000 submitted abstracts. The NRG Oncology presentations at the meeting will include results from trials for patients with brain tumors, spine metastases, or anal, breast, cervix, genitourinary, gynecologic, head and neck, liver, lung, or prostate cancer. Read more

August 14 2019

NRG-GY018: Kit Ordering

Please be advised that there is approximately a 10-day turnaround time to receive a kit from the day a kit is requested. There is no ability to expedite a kit shipment. Please consent your patients accordingly. Read more

August 12 2019

Weekly Broadcast

NSABP B-55, NRG-BN001, NRG-GI004, NRG-GY005, NRG-GY009, NRG-GY018 Read more

August 08 2019

NRG-CC007CD: Re-opened to Practice

NRG-CC007CD is now re-open to practice randomization. Read more

August 05 2019

Weekly Broadcast

RTOG 1112, NRG-GU006, NRG-GY014, NRG-GY005, NRG-GY009, NRG-LU005 Read more

July 29 2019

Special Edition - July 2019 NRG Meeting

Read more

July 26 2019

NRG-GY014

Suspended to endometrial patients, ovarian suspension imminent Read more

July 24 2019

NRG Oncology is seeking an experienced Patient Advocate to serve as Chair for its Patient Advocate Committee

Read more

July 01 2019

Independence Day Holiday Closures for Operations, SDMCs, Biospecimen Banks, Serum Bank, and McKesson Clinical Research Services.

Read more

June 03 2019

Patients who Received Partial Breast Irradiation without Chemotherapy Experienced Less Fatigue, Slightly Poorer Cosmesis on NRG Oncology Trial

Patient-reported outcome (PRO) data indicates that partial breast irradiation (PBI) is more convenient than whole breast irradiation (WBI) for women with breast cancer who do not receive adjuvant chemotherapy. These participants on the NRG Oncology clinical trial NSABP B-39/RTOG 0413 also experienced less post-treatment fatigue and slightly poorer cosmesis at 36 months following treatment, whereas cosmesis was equivalent at 36 months in women who received chemotherapy and PBI or WBI. These outcomes were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting and the abstract was designated as a “Best of ASCO” abstract. Read more

June 03 2019

NRG Oncology Trial Sets New Standard Regimen for Women with Uterine Carcinosarcomas

Results from the phase III NRG Oncology clinical trial GOG 0261 comparing paclitaxel plus carboplatin (PC) to paclitaxel plus ifosfamide (PI) in women with stage I-IV, recurrent carcinosarcoma of the uterus or ovary, indicate that the PC combination treatment should be considered a standard of care for this patient population. The study concludes that among uterine cancer patients treatment with PC was not inferior to PI based on the primary objective overall survival (OS), and PC was associated with longer progression-free survival (PFS) outcomes when compared with PI. These results were recently presented at the American Society for Clinical Oncology (ASCO) Annual Meeting and was awarded a “Best of ASCO” designation. Read more

June 03 2019

Analyses of NRG Oncology/RTOG 9802 Suggests Both IDH-mutant WHO-defined Molecular Subgroups of High-risk Low-Grade Gliomas May Benefit from the Addition of PCV Chemotherapy to Radiotherapy

A recent, updated predictive analysis of the three WHO-defined molecular subgroups based on isocitrate dehydrogenase 1/2 (IDH) mutation status and 1p/19q co-deletion status represented in the high-risk treatment arms of the NRG Oncology clinical trial NRG-RTOG 9802 indicates that both IDH-mutant sub-groups (IDHmut-noncodel and IDHmut-codel) could benefit from the addition of PCV chemotherapy to radiotherapy treatment. This data was presented during a “Best of ASCO” oral presentation in the Central Nervous Systems Tumors Session at the American Society of Clinical Oncology (ASCO) Annual Meeting. Read more

June 01 2019

Initial Experimental Treatment Arm Results from NRG Oncology Trial Suggests Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer is Safe

Results from the first experimental arm using veliparib as part of total neoadjuvant therapy (induction chemotherapy followed by chemoradiotherapy and surgery; TNT) in patients with locally advanced rectal adenocarcinoma on the NRG Oncology Phase II clinical trial NRG-GI002 were recently presented at the American Society of Clinical Oncology (ASCO) Annual Meeting. Results were reported on the primary endpoint of pathological regression via the neoadjuvant rectal cancer (NAR) score, a short-term clinical trial surrogate endpoint. Read more

June 01 2019

NRG Oncology Trial Shows Tolerability of Metformin for Non-Small Cell Lung Cancer, No Improvement in Survival Outcomes between Treatments

Initial results of NRG-LU001 indicate that, although the diabetes agent metformin was well-tolerated by patients, the agent has not clearly improved progression-free survival (PFS) or overall survival (OS) for trial participants with locally advanced non-small cell lung cancer (NSCLC). These results are based on local center reported outcomes. Trial participants will continue to be followed for changes in their status. The initial report of these results were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting and the abstract was awarded a “Best of ASCO” designation. Read more

May 20 2019

Memorial Day closures for Operations, SDMCs, Biospecimen Banks, Serum Bank, and McKesson Clinical Research Services.

Read more

May 03 2019

Patient Reported Outcomes: Upping the game for PRO methods and design in clinical trials

Read more

April 23 2019

Project Team Member Application – Abemaciclib

Read more

April 17 2019

NRG Oncology SDMC Awarded NCI Funding for Next 6 Years with ‘Outstanding’ Score

The NRG Oncology Statistics and Data Management Center (SDMC) was notified that the center will be awarded six more years of funding from the National Cancer Institute (NCI) and will continue to serve the NCI National Clinical Trials Network (NCTN) group NRG Oncology. The total amount of funding requested for the six year effort was $68.9 million. During the peer review grant renewal process, the NRG Oncology SDMC was ranked within the “Outstanding” range with a score of 18. Read more

April 16 2019

NRG Oncology Awarded NCI Funding for Next 6 Years, Receives "Exceptional" Score

NRG Oncology, a National Cancer Institute (NCI) National Clinical Trials Network (NCTN) group conducting practice-changing clinical and translational research, has been awarded funding of $16.5 Million by the NCI for the next six years to continue its work as a lead protocol organization (LPO) program. During the peer review grant renewal process, NRG Oncology received the “exceptional” score of 16. Read more

March 18 2019

Prophylactic Cranial Irradiation Improves Disease-Free Survival and Brain Metastasis Rates for Locally Advanced Non-Small Cell Lung Cancer

Prophylactic cranial irradiation (PCI), a technique used to prevent the clinical development of brain metastases, is established as a standard approach for many patients with small cell lung cancer (SCLC) after initial therapy. While studies established that PCI decreases the incidence of brain metastases for patients with locally advanced non-small cell lung cancer (LA-NSCLC), there is no established indication for its use for such NSCLC patients. Read more

March 12 2019

NRG Oncology Trial Suggests Adding Docetaxel-based Chemotherapy to Standard Treatment Should be Considered for Men with High-Risk Prostate Cancer

According to the American Cancer Society, prostate cancer is the second most common cause of cancer-related death among men in the United States in 2018. Currently, the standard of care treatment for high-risk, localized prostate cancer is a combination of radiotherapy (RT) and long-term (24-36 month) androgen suppression (AS). Researchers theorized that adding adjuvant docetaxel, a cytotoxic chemotherapy drug, to the standard of care RT and long-term AS treatment could potentially improve overall survival and clinical outcomes for men with localized, high-risk prostate cancer. Read more

March 05 2019

Project Team Member Application – BAY 1895344

Read more

February 21 2019

NRG Oncology NCORP Pilot Projects

Read more

February 15 2019

NRG Oncology Trial Affirms Hypofractionated Radiotherapy Should Be Considered New Practice Standard for Men with Low Risk Prostate Cancer

Results from the NRG Oncology clinical study NRG-RTOG 0415 determined that a hypofractionated radiotherapy schedule (H-RT), a treatment schedule that delivers a total dose of radiotherapy over a shorter period of time, is not worse than the conventional radiotherapy schedule (C-RT) in terms of bowel, bladder, sexual, and general quality of life (QOL) as well as anxiety and depression for men with low risk prostate cancer. Read more

December 20 2018

Time to Biochemical Failure Could be Used as a Surrogate Endpoint in Treatment of Locally Advanced Prostate Cancer

An analysis of the NRG Oncology clinical trial NRG-RTOG 9202 showed that the interval of time to biochemical failure (IBF), or the time it takes for previously treated cancer to return as indicated by prostate specific antigen (PSA) rise, could be used as a surrogate endpoint for locally advanced prostate cancer. Read more

December 18 2018

December 18, 2018 - Join the Head and Neck Cancer Alliance in Celebrating the 2019 Oral, Head and Neck Cancer Awareness Week®, April 7-14

Read more

December 17 2018

December 17, 2018

Read more

December 17 2018

December 17, 2018 - Project Team Member Application – Hu5F9-G4

Read more

December 13 2018

December 13, 2018 - NCTN and NCORP CIRB Requirement Policy: Implementation Date Effective March 1, 2019

Read more

December 06 2018

Accelerated Partial Breast Irradiation, Although Close, was Not Equivalent to Whole Breast Irradiation To Control Ipsilateral Breast Tumor Recurrence

Data from the NRG (NSABP B-39/RTOG 0413) trial indicated that ipsilateral breast tumor recurrence (IBTR) rates 10 years after treatment could not reject the hypothesis that accelerated partial breast irradiation (PBI) after lumpectomy was inferior to whole breast irradiation (WBI), according to a presentation at the 2018 San Antonio Breast Cancer Symposium, held Dec. 4–8. Read more

November 29 2018

Tocagen and NRG Oncology to Collaborate on a Phase 2/3 Trial of Toca 511 & Toca FC in Newly Diagnosed Glioblastoma

Tocagen Inc. (Nasdaq: TOCA), a late clinical-stage, cancer-selective gene therapy company and NRG Oncology, a member of the National Cancer Institute’s (NCI) National Clinical Trial Network (NCTN), today announced that the NCI Cancer Therapy and Evaluation Program (CTEP) Brain Malignancies Steering Committee has approved a concept to develop a clinical trial utilizing the investigational therapeutic regimen Toca 511 (vocimagene amiretrorepvec) & Toca FC (flucytosine, extended-release) for the treatment of patients with newly diagnosed glioblastoma (GBM). Read more

November 12 2018

November 12, 2018

Read more

November 05 2018

November 5, 2018

Read more

September 13 2018

September 13, 2018 Project Team Member Application – DS-8201a

Read more

August 27 2018

August 27, 2018

Read more

August 23 2018

August 23, 2018

Read more

July 19 2018

July 19, 2018

Read more

June 25 2018

June 25, 2018

Read more

June 25 2018

June 25, 2018

Read more

June 18 2018

June 18, 2018 - An Important Word from Quality Assurance About Protocol Amendments

Read more

May 21 2018

May 21, 2018

Read more

May 07 2018

May 7, 2018 - Project Team Member Application – Rogaratinib

Read more

April 04 2018

April 4, 2018 Dr. Chakravarti Selected to Serve on NCI Advisory Board of Scientific Counselors

Read more

March 30 2018

March 30, 2018 Dr. Felix Feng Selected as the New NRG Oncology Genitourinary Cancer Committee Chair

Read more

March 23 2018

March 23, 2018

Read more

March 12 2018

March 12, 2018 - Project Team Member Application – Radium-223

Read more

March 07 2018

March 7, 2018

Read more

February 19 2018

February 19, 2018 - NRG Oncology NCORP Pilot Projects

Read more

February 14 2018

February 14, 2018 - NRG Oncology Appoints NCORP Investigator, Matthew Hudson, as Cancer Care Delivery Research Committee Co-Chair

Read more

February 13 2018

February 13, 2018 - Aghajanian Appointed as NRG Oncology Gynecologic Cancer Committee Chair

Read more

February 01 2018

February 1, 2018 - NRG Oncology Appoints Kati Stoermer for New Executive Director Role

Read more

Stay current with science. Sign up for our newsletter.

Support NRG Oncology.
Help Our Cause.

We are a leading protocol organizations within the National Clinical Trials Network and we seek to improve the lives of cancer patients by conducting practice-changing, multi-institutional clinical and translational research. Learn More

Donate Today

NRG Oncology Foundation, Inc, is a nonprofit, tax-exempt foundation. Donations to NRG Oncology help us conduct this important mission, and are tax-deductible to the extent permitted by law.